Moulton K S
Cardiovascular Division, Brigham and Women's Hospital, and Surgical Research, Children's Hospital, 300 Longwood Avenue, Enders 10, Boston, MA 02115, USA.
Curr Atheroscler Rep. 2001 May;3(3):225-33. doi: 10.1007/s11883-001-0065-0.
Therapeutic angiogenesis trials refer to the stimulation of collateral arterioles and new vascular conduits to perfuse ischemic myocardium and limbs. Atherosclerotic lesions responsible for vascular occlusions themselves are associated with angiogenesis within the vessel wall. Plaque neovascularization is comprised of a network of capillaries that arise from the adventitial vasa vasorum and extend into the intimal layer of atherosclerotic lesions and other types of vascular injury. The functions of these plaque capillaries are proposed to be important regulators of plaque growth and lesion instability. The development of agents that are positive and negative regulators of angiogenesis may have potential therapeutic implications in the progression and acute manifestations of atherosclerosis. This review focuses on the role of plaque angiogenesis in atherosclerosis and discusses the potential therapeutic applications of angiogenesis inhibitors in this disease.
治疗性血管生成试验是指刺激侧支小动脉和新的血管管道，以灌注缺血的心肌和肢体。导致血管闭塞的动脉粥样硬化病变本身与血管壁内的血管生成有关。斑块新生血管形成由源自外膜血管滋养管的毛细血管网络组成，并延伸至动脉粥样硬化病变和其他类型血管损伤的内膜层。这些斑块毛细血管的功能被认为是斑块生长和病变不稳定的重要调节因子。血管生成正负调节因子的研发可能对动脉粥样硬化的进展和急性表现具有潜在的治疗意义。本综述重点关注斑块血管生成在动脉粥样硬化中的作用，并讨论血管生成抑制剂在该疾病中的潜在治疗应用。
